期刊
CURRENT OPINION IN PHARMACOLOGY
卷 10, 期 2, 页码 146-155出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2009.12.001
关键词
-
资金
- American Heart Association [0625937T, SDG 0930360N]
- National Institute of Health [HL-088637, HL-064839, HL-077789]
- AHA [0740013N]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL102746, R01HL064839, R01HL088637, P01HL077789] Funding Source: NIH RePORTER
Sumoylation is a covalent modification, which is mediated by small ubiquitin-like modifier (SUMO) polypeptides. A growing body of evidence has shown that sumoylation affects the functional properties of many substrates in the regulation of cellular processes. Recent reports indicate the crucial role of sumoylation in human diseases including familial dilated cardiomyopathy, suggesting that targeting of sumoylation would be of considerable interest for novel therapies. Even though hundreds of SUMO substrates have been identified, their pathophysiological roles remain to be determined. Among them, ERK5-sumoylation has recently been linked to diabetes and implicated in endothelial dysfunction and cardiomyocyte apoptosis in vivo. These findings support the idea that ERK5-sumoylation is a novel therapeutic target for the treatment of diabetes-related cardiovascular diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据